Eric Small, MD
Professor
Medicine
School of Medicine

I subsequently was centrally involved with the development of two novel androgen signaling inhibitors, abiraterone acetate and apalutamide, from first in human studies to FDA approval.

I have also been involved in the early application of immunotherapy to prostate cancer, developing sipuleucel T from first in human studies through FDA approval, and undertaking the first in human testing of ipilimumab, the first immune check point inhibitor to be clinically developed.

Understanding the mechanisms of resistance in advanced prostate cancer has been a research focus. I was principal investigator of a $10 million multi-center Stand Up to Cancer (SU2C)/Prostate Cancer Foundation Dream Team Award undertaking deep genomic characterization of prostate cancer metastases, in order to elucidate patterns of resistance in abiraterone and/or enzalutamide treated patients. Important observations from this, and subsequent work have included unexpectedly high prevalence rates of treatment associated small cell/neuroendocrine prostate cancer (t-SCNC), as well as key structural variants which contribute to progression of castration-resistant disease.

I hold a number of leadership roles, serving as Co-Leader of the UCSF Prostate Cancer Program, and as Deputy Director of the UCSF Helen Diller Family Comprehensive Cancer Center. I previously served as Chief of the Division of Hematology and Oncology in the UCSF Department of Medicine for 10 years, and most recently have assumed the position of Chief Scientific Officer in the UCSF Helen Diller Family Comprehensive Cancer Center. Nationally, I serve on the ASCO Board of Directors, and chair of 4 External Advisory Boards for other NCI Designated Cancer Centers.

• Cancer Research in 2030: A unique strategic planning process at a comprehensive cancer center.
  Preventive oncology & epidemiology 2023 Bank EM, Small EJ, Ashworth A, Hiatt RA
• Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
  British journal of cancer 2023 Shen J, Chowdhury S, Agarwal N, Karsh LI, Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN, Brookman-May SD, Rooney B, Bhaumik A, McCarthy SA, Bevans KB, Mundle SD, Small EJ, Smith MR…
• Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
  The Lancet. Oncology 2023 Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong…
• The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.
  Cancer research 2023 Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, Sjöström M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein AS, Younger N, Alumkal JJ, Beer TM, Chi KN, Evans CP, …
• Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Small EJ
• Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
  Clinical genitourinary cancer 2023 Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal …
• External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN, de Bono JS, Petrylak DP, Fizazi K, Higano CS, Morris MJ, Rathkopf DE, Saad F, Ryan CJ, Small …
• Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
  Frontiers in oncology 2023 Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou…
• Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, Bryce AH, Hahn O, Beltran H, Armstrong AJ, Schwartz L, Lewis LD, Beumer JH, Langevin B, McGary EC, Mehan PT, Goldkorn A, Roth BJ, Xiao…
• Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, …
• Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
  European journal of cancer (Oxford, England : 1990) 2023 Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, …
• Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
  Cancer research 2023 Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, …
• Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer.
  JCO oncology practice 2023 Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, Schleicher A, Aggarwal RR, Blanco AM, Small EJ, Dhawan M
• Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Feng E, Rydzewski NR, Zhang M, Lundberg A, Bootsma M, Helzer KT, Lang JM, Aggarwal R, Small EJ, Quigley DA, Sjöström M, Zhao SG
• Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention.
  Urologic oncology 2022 Langlais CS, Chen YH, Van Blarigan EL, Chan JM, Ryan CJ, Zhang L, Borno HT, Newton RU, Luke A, Bang AS, Panchal N, Tenggara I, Schultz B, Lavaki E, Pinto N, Aggarwal R, Friedlander T, Koshkin VS, …
• Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
  European urology 2022 Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, …
• Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic.
  JAMA oncology 2022 Ragavan MV, Legaspi N, LaLanne A, Hong JC, Small EJ, Borno HT
• Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
  Urologic oncology 2022 Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ
• Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study.
  Journal of immigrant and minority health 2022 Borno HT, Kim MO, Tolstykh I, Lin A, Hong JC, Yousefi S, Zhang S, McKay RR, Harismendy O, Razavi P, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ
• The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
  Cancer research 2022 Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, …
• Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
  Prostate cancer and prostatic diseases 2022 Pollock Y, Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik B, Olmos D, Lee JY, Uemura H, Bhaumik A, Londhe A, Rooney B, Brookman-May SD, De Porre P, Mundle SD, Small EJ
• Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.
  Prostate cancer 2022 Aggarwal R, Alumkal JJ, Szmulewitz RZ, Higano CS, Bryce AH, Lopez-Gitlitz A, McCarthy SA, Miladinovic B, McQuarrie K, Thomas S, Zhang K, Small EJ
• Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
  Nature communications 2022 Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, …
• Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
  Urologic oncology 2022 Tamukong PK, Kuhlmann P, You S, Su S, Wang Y, Yoon S, Gong J, Figlin RA, Janes JL, Freedland SJ, Halabi S, Small EJ, Rini BI, Kim HL
• Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
  Nature 2022 Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, Korhonen OV, Munzur AD, Beja K, Schönlau E, Bernales CQ, Ritch E, Bacon JVW, Lack NA, Nykter M, Aggarwal R, Small EJ, Gleave ME, SU2C/PCF …
• CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, Small EJ, Chou J, Wells JA, …
• Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Nixon AB, Halabi S, Liu Y, Starr MD, Brady JC, Shterev I, Luo B, Hurwitz HI, Febbo PG, Rini BI, Beltran H, Small EJ, Morris MJ, George DJ
• Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset.
  Urologic oncology 2022 Kwon DH, Paciorek A, Zhang L, Borno HT, Bucknor M, Small EJ, Aggarwal RR
• COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry.
  The oncologist 2022 Borno HT, Kim MO, Hong JC, Yousefi S, Lin A, Tolstykh I, Zhang S, McKay RR, Harismendy O, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ
• Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study.
  JCO clinical cancer informatics 2022 Borno HT, Zhang L, Zhang S, Kaplan C, Palmer NR, Bell A, Bakke B, Lin A, Aggarwal R, Small EJ
• Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]).
  European urology focus 2022 Kellogg Parsons J, Zahrieh D, Patel D, Mohler JL, Chen RC, Paskett ED, Liu H, Peil ES, Rock CL, Hahn O, Taylor J, Van Veldhuizen PJ, Small EJ, Morris MJ, Naughton MJ, Pierce JP, Marshall J
• Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
  European urology 2022 Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou …
• Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].
  European urology 2022 Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, …
• A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 de Kouchkovsky I, Rao A, Carneiro BA, Zhang L, Lewis C, Phone A, Small EJ, Friedlander T, Fong L, Paris PL, Ryan CJ, Szmulewitz RZ, Aggarwal R
• APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
  Frontiers in oncology 2022 Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J,…
• Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical Trial.
  JCO oncology practice 2022 Borno HT, Zhang L, Zhang S, Lin TK, Skafel A, Nieves E, Dornsife D, Johnson R, Rhoads K, Small E, Spicer D
• What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
  European urology 2022 Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, …
• Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer.
  JCO oncology practice 2021 Kwon DH, Karthikeyan S, Chang A, Borno HT, Koshkin VS, Desai A, Bose R, Friedlander T, Rodvelt T, Li P, Small EJ, Aggarwal RR, Belkora J
• The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
  Nature communications 2021 Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, Chakravarti D, Warfel NA, Zhou M, Bearss JJ, …
• Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
  European urology 2021 Saad F, Small EJ, Feng FY, Graff JN, Olmos D, Hadaschik BA, Oudard S, Londhe A, Bhaumik A, Lopez-Gitlitz A, Thomas S, Mundle SD, Chowdhury S, Smith MR
• Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings.
  European journal of cancer (Oxford, England : 1990) 2021 Vogl UM, Beer TM, Davis ID, Shore ND, Sweeney CJ, Ost P, Attard G, Bossi A, de Bono J, Drake CG, Efstathiou E, Fanti S, Fizazi K, Halabi S, James N, Mottet N, Padhani AR, Roach M, Rubin M, Sartor O, …
• Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.
  JAMA oncology 2021 Aggarwal R, Rydzewski NR, Zhang L, Foye A, Kim W, Helzer KT, Bakhtiar H, Chang SL, Perry MD, Gleave M, Reiter RE, Huang J, Evans CP, Alumkal JJ, Lang JM, Yu M, Quigley DA, Sjöström M, Small EJ, Feng …
• Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer.
  Cancer medicine 2021 Kenfield SA, Van Blarigan EL, Panchal N, Bang A, Zhang L, Graff RE, Chen YH, Ryan CJ, Luke A, Newton RU, Tenggara I, Schultz B, Wang E, Lavaki E, Zuniga K, Pinto N, Borno H, Aggarwal R, Friedlander T,…
• Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures.
  NPJ genomic medicine 2021 Rydzewski NR, Peterson E, Lang JM, Yu M, Laura Chang S, Sjöström M, Bakhtiar H, Song G, Helzer KT, Bootsma ML, Chen WS, Shrestha RM, Zhang M, Quigley DA, Aggarwal R, Small EJ, Wahl DR, Feng FY, Zhao …
• Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis.
  Journal of cancer policy 2021 Borno HT, Lin TK, Zhang S, Skafel A, Lalanne A, Dornsife D, Johnson R, Spicer D, Small EJ, Rhoads KF
• Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
  European urology focus 2021 Oudard S, Hadaschik B, Saad F, Cella D, Basch E, Graff JN, Uemura H, Dibaj S, Li S, Brookman-May SD, De Porre P, Bevans KB, Trudeau JJ, Small EJ, Smith MR
• An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer.
  Nature communications 2021 Das R, Sjöström M, Shrestha R, Yogodzinski C, Egusa EA, Chesner LN, Chen WS, Chou J, Dang DK, Swinderman JT, Ge A, Hua JT, Kabir S, Quigley DA, Small EJ, Ashworth A, Feng FY, Gilbert LA
• A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study.
  Urologic oncology 2021 Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, …
• Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
  JAMA oncology 2021 Feng FY, Thomas S, Saad F, Gormley M, Yu MK, Ricci DS, Rooney B, Brookman-May S, McCarthy S, Olmos D, Chowdhury S, Hadaschik B, Liu Y, Davicioni E, Smith MR, Small EJ
• BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Kim DH, Sun D, Storck WK, Welker Leng K, Jenkins C, Coleman DJ, Sampson D, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman JA, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, …
• Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Smith MR, Thomas S, Gormley M, Chowdhury S, Olmos D, Oudard S, Feng FY, Rajpurohit Y, Urtishak K, Ricci DS, Rooney B, Lopez-Gitlitz A, Yu M, Wyatt AW, Li M, Attard G, Small EJ
• Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Rosenberg JE, Ballman KA, Halabi S, Atherton PJ, Mortazavi A, Sweeney C, Stadler WM, Teply BA, Picus J, Tagawa ST, Katragadda S, Vaena D, Misleh J, Hoimes C, Plimack ER, Flaig TW, Dreicer R, Bajorin D…
• Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
  Journal for immunotherapy of cancer 2021 Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal R, Spitzer M, Allison JP, Small EJ, Sharma P, Fong L
• TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
  Journal for immunotherapy of cancer 2021 de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, …
• Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.
  European urology 2021 Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, …
• Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality.
  Cancer 2021 Bitterman DS, Chen MH, Wu J, Renshaw AA, Loffredo M, Kantoff PW, Small EJ, D'Amico AV
• Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance).
  The Journal of urology 2021 Eastham JA, Heller G, Hillman DW, Hahn OM, Parsons JK, Mohler JL, Small EJ, Morris M
• Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
  Cancer 2021 Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS
• Examining reporting and representation of patients with cancer in COVID-19 clinical trials.
  Cancer reports (Hoboken, N.J.) 2021 Rabow M, Wang C, Zhang S, Tahir PM, Small EJ, Borno HT
• Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry.
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Kwon DH, Vashisht R, Borno HT, Aggarwal RR, Small EJ, Butte AJ, Huang FW
• MicroRNA-574 regulates FAM210A expression and influences pathological cardiac remodeling.
  EMBO molecular medicine 2020 Wu J, Venkata Subbaiah KC, Jiang F, Hedaya O, Mohan A, Yang T, Welle K, Ghaemmaghami S, Tang WHW, Small E, Yan C, Yao P
• Accelerating precision medicine in metastatic prostate cancer.
  Nature cancer 2020 Mateo J, McKay R, Abida W, Aggarwal R, Alumkal J, Alva A, Feng F, Gao X, Graff J, Hussain M, Karzai F, Montgomery B, Oh W, Patel V, Rathkopf D, Rettig M, Schultz N, Smith M, Solit D, Sternberg C, Van …
• Autoantibody Landscape in Patients with Advanced Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M…
• Apalutamide and Overall Survival in Prostate Cancer.
  European urology 2020 Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Brookman-May SD, Li S, Zhang K, Rooney B, Lopez-Gitlitz A, Small EJ
• Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, …
• Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Eastham JA, Heller G, Halabi S, Monk JP, Beltran H, Gleave M, Evans CP, Clinton SK, Szmulewitz RZ, Coleman J, Hillman DW, Watt CR, George S, Sanda MG, Hahn OM, Taplin ME, Parsons JK, Mohler JL, Small …
• A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, Attwell S, Norek K, Snyder M, Bauman L, Lakhotia S, Feng FY, Small EJ, Abida W, Alumkal JJ
• The DNA methylation landscape of advanced prostate cancer.
  Nature genetics 2020 Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, …
• Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.
  Urologic oncology 2020 Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN, Thomas GV, Li P, Lui A, Small …
• Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Perez-Ruixo C, Ackaert O, Ouellet D, Chien C, Uemura H, Olmos D, Mainwaring P, Lee JY, Yu MK, Perez-Ruixo JJ, Smith MR, Small EJ
• Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study.
  Prostate international 2020 Uemura H, Satoh T, Tsumura H, Arai G, Imanaka K, Shibayama K, Fujii K, Rooney B, Lopez-Gitlitz A, Espina B, Perez-Ruixo C, Small EJ, Smith M
• Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
  Proceedings of the National Academy of Sciences of the United States of America 2020 Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, …
• Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.
  Prostate cancer and prostatic diseases 2020 Aggarwal R, Romero GR, Friedl V, Weinstein A, Foye A, Huang J, Feng F, Stuart JM, Small EJ
• Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research?
  Contemporary clinical trials 2020 Borno HT, Small EJ
• Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.
  Prostate cancer and prostatic diseases 2020 Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, Schellhammer PF, Harmon …
• Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel.
  JNCI cancer spectrum 2020 Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly …
• Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
  European urology 2020 Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, …
• Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.
  JAMA 2020 Parsons JK, Zahrieh D, Mohler JL, Paskett E, Hansel DE, Kibel AS, Liu H, Seisler DK, Natarajan L, White M, Hahn O, Taylor J, Hartman SJ, Stroup SP, Van Veldhuizen P, Hall L, Small EJ, Morris MJ, …
• Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer.
  Prostate cancer and prostatic diseases 2019 Chen WS, Feng EL, Aggarwal R, Foye A, Beer TM, Alumkal JJ, Gleave M, Chi KN, Reiter RE, Rettig MB, Evans CP, Small EJ, Sharifi N, Zhao SG
• A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching tool.
  Pilot and feasibility studies 2019 Borno HT, Bakke BM, Kaplan C, Hebig-Prophet A, Chao J, Kim YJ, Yeager J, Cinar P, Small E, Boscardin C, Gonzales R
• Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer.
  Clinical genitourinary cancer 2019 Smith MR, Mehra M, Nair S, Lawson J, Small EJ
• Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study.
  Prostate cancer and prostatic diseases 2019 Chen HY, Aggarwal R, Bok RA, Ohliger MA, Zhu Z, Lee P, Gordon JW, van Criekinge M, Carvajal L, Slater JB, Larson PEZ, Small EJ, Kurhanewicz J, Vigneron DB
• Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.
  Annals of oncology : official journal of the European Society for Medical Oncology 2019 Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Zhang K, Lopez-Gitlitz A, Smith MR
• How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials.
  Contemporary clinical trials communications 2019 Borno HT, Small EJ, Zhang L, DeRouen MC, Griffin A, McGuire J, Ryan CJ, Hiatt RA, Kaplan CP
• Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
  European urology 2019 Reimers MA, Yip SM, Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW, Chi KN, Small EJ, Chinnaiyan AM, Alva AS, Feng FY, Chou J
• Ethnic disparities among men with prostate cancer undergoing germline testing.
  Urologic oncology 2019 Kwon DH, Borno HT, Cheng HH, Zhou AY, Small EJ
• Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, …
• Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
  The oncologist 2019 George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK
• The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker A, Arnold J, Hecht T, Wicha M, Sears R, Rowley D, White R, Gulley JL, Lee J, Diaz Meco M, Small EJ, Shen M, …
• Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors.
  Future oncology (London, England) 2019 Desai A, Small EJ
• Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
  JAMA oncology 2019 Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R,…
• Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).
  Prostate cancer and prostatic diseases 2019 Ryan CJ, Dutta S, Kelly WK, Russell C, Small EJ, Morris MJ, Taplin ME, Halabi S, From The Alliance for Clinical Trials in Oncology Genitourinary Committee
• Germline and Somatic Mutations in Prostate Cancer for the Clinician.
  Journal of the National Comprehensive Cancer Network : JNCCN 2019 Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS
• Incidentally Detected Oropharyngeal Squamous Cell Carcinoma on 18F-Fluciclovine PET/CT.
  Clinical nuclear medicine 2019 Raghavan K, Wen KW, Small EJ, Ha P, Flavell RR
• Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2019 Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, …
• Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, Small EJ, Nguyen PL, Feng FY
• Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
  European urology 2019 Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, …
• Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.
  Molecular cancer research : MCR 2019 Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ
• MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
  Prostate cancer and prostatic diseases 2019 Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, …
• Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases.
  Clinical nuclear medicine 2019 Perez PM, Hope TA, Behr SC, van Zante A, Small EJ, Flavell RR
• Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small…
• Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, …
• Reply to A. Dalla Volta et al.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Aggarwal R, Huang J, Alumkal J, Feng FY, Zhang L, Stuart JM, Small EJ
• Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2018 Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, …
• Apalutamide and its use in the treatment of prostate cancer.
  Future oncology (London, England) 2018 Borno HT, Small EJ
• Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials.
  Therapeutic advances in urology 2018 Koshkin VS, Small EJ
• Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series.
  Prostate cancer and prostatic diseases 2018 Mohler JL, Halabi S, Ryan ST, Al-Daghmin A, Sokoloff MH, Steinberg GD, Sanford BL, Eastham JA, Walther PJ, Morris MJ, Small EJ
• Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
  Cell 2018 Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, …
• Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].
  European journal of cancer (Oxford, England : 1990) 2018 Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ
• Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.
  Clinical genitourinary cancer 2018 Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R
• Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
  The Lancet. Oncology 2018 Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ
• Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
  JCI insight 2018 Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B
• A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy.
  Contemporary clinical trials communications 2018 Kaplan CP, Siegel A, Leykin Y, Palmer NR, Borno H, Bielenberg J, Livaudais-Toman J, Ryan C, Small EJ
• DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
  Journal of the National Comprehensive Cancer Network : JNCCN 2018 Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ
• Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
  Cell 2018 Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, …
• Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D,…
• Apalutamide and Metastasis-free Survival in Prostate Cancer.
  The New England journal of medicine 2018 Smith MR, Yu MK, Small EJ
• Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Antonarakis ES, Small EJ, Petrylak DP, Quinn DI, Kibel AS, Chang NN, Dearstyne E, Harmon M, Campogan D, Haynes H, Vu T, Sheikh NA, Drake CG
• Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
  European urology oncology 2018 Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T
• Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
  European journal of cancer (Oxford, England : 1990) 2018 Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ
• Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
  The New England journal of medicine 2018 Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ, SPARTAN …
• Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
  Clinical genitourinary cancer 2017 Wei XX, Perry J, Chang E, Zhang L, Hiatt RA, Ryan CJ, Small EJ, Fong L
• Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
  Cancer 2017 Atkins KM, Chen MH, Wu J, Renshaw AA, Loffredo M, Kantoff PW, Small EJ, D'Amico AV
• Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
  Journal of the National Cancer Institute 2017 Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME
• Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer.
  EJNMMI research 2017 Lake ST, Greene KL, Westphalen AC, Behr SC, Zagoria R, Small EJ, Carroll PR, Hope TA
• Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies.
  Cancer cell 2017 Small EJ
• Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies.
  Cancer cell 2017 Small EJ
• Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making.
  JCO precision oncology 2017 Tao DL, Bailey S, Beer TM, Foss E, Beckett B, Fung A, Foster BR, Guimaraes A, Cetnar JP, Graff JN, Eilers KM, Small EJ, Corless CL, Thomas GV, Alumkal JJ
• Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications.
  Oncology (Williston Park, N.Y.) 2017 Aggarwal RR, Feng FY, Small EJ
• Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.
  Molecular cancer research : MCR 2017 Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ
• High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.
  Clinical genitourinary cancer 2017 Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R…
• Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
  Expert review of anticancer therapy 2017 Anantharaman A, Small EJ
• CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield.
  Journal of vascular and interventional radiology : JVIR 2017 Holmes MG, Foss E, Joseph G, Foye A, Beckett B, Motamedi D, Youngren J, Thomas GV, Huang J, Aggarwal R, Alumkal JJ, Beer TM, Small EJ, Link TM
• Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer.
  BJU international 2017 Parsons JK, Pierce JP, Mohler J, Paskett E, Jung SH, Morris MJ, Small E, Hahn O, Humphrey P, Taylor J, Marshall J
• Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017 Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR
• Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
  Cancer discovery 2017 Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, …
• Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
  European urology 2017 Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ
• Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer.
  Oncotarget 2017 Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, Alumkal JJ, Beer TM, Thomas GV
• Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
  European urology 2017 Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW
• A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
  Urologic oncology 2017 Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ
• A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer.
  Molecular imaging and biology 2016 Behr SC, Aggarwal R, Seo Y, Aparici CM, Chang E, Gao KT, Tao DH, Small EJ, Evans MJ
• Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ
• Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team.
  European urology focus 2016 Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, Youngren J, Alumkal JJ, Huang J, Thomas G, Witte O, Small EJ
• Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.
  Cancer immunology research 2016 Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L
• 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2016 Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ
• Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
  European urology 2016 de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW
• An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.
  Cancer letters 2016 Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, …
• Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev…
• Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, …
• Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis …
• Prospects for the use of ipilimumab in treating advanced prostate cancer.
  Expert opinion on biological therapy 2016 Wei XX, Fong L, Small EJ
• Prostate Cancer, Version 1.2016.
  Journal of the National Comprehensive Cancer Network : JNCCN 2016 Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER…
• Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.
  The Canadian journal of urology 2015 Crawford ED, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, Shore ND, Ferrari A
• Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
  European urology 2015 Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan …
• Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
  Expert review of vaccines 2015 Wei XX, Fong L, Small EJ
• Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients.
  Contemporary clinical trials 2015 Kaplan CP, Nápoles AM, Narine S, Gregorich S, Livaudais-Toman J, Nguyen T, Leykin Y, Roach M, Small EJ
• A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).
  EBioMedicine 2015 Kim HL, Halabi S, Li P, Mayhew G, Simko J, Nixon AB, Small EJ, Rini B, Morris MJ, Taplin ME, George D, Alliance for Clinical Trials in Oncology
• Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
  European urology 2015 Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, …
• Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.
  Cancer immunology research 2015 Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L
• A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, Shore ND
• Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, Small EJ, Wang Y, Gleave ME, Collins CC, Chi KN
• Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
  Cancer 2015 Halabi S, Rini BI, Escudier B, Stadler WM, Small EJ
• Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ, Kantoff PW, Higano CS, Small EJ, Gardner TA, Bailey K, Vu T, DeVries T, Whitmore JB, Frohlich MW, Trager JB, Drake CG
• Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ
• Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
  The Lancet. Oncology 2015 Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu…
• Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
  Clinical genitourinary cancer 2014 Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ
• Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
  Cancer 2014 Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL
• Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ
• Can targeting the androgen receptor in localized prostate cancer provide insights into why men with metastatic castration-resistant prostate cancer die?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Small EJ
• Small-cell/neuroendocrine prostate cancer: a growing threat?
  Oncology (Williston Park, N.Y.) 2014 Aggarwal RR, Small EJ
• Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.
  Journal of the National Cancer Institute 2014 Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ
• Reply to F. Valcamonico et al.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Smith MR, Halabi S, Small EJ
• A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.
  Cancer immunology research 2014 McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, Sims RB, DeVries T, Sheikh NA, Dreicer R
• Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate.
  Prostate cancer and prostatic diseases 2014 Kim W, Jones JO, Diamond M, Haqq C, Molina A, Small EJ, Ryan CJ
• Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.
  Prostate cancer and prostatic diseases 2014 Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP
• Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Aggarwal R, Zhang T, Small EJ, Armstrong AJ
• Prostate cancer, version 2.2014.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D,…
• Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
  Clinical genitourinary cancer 2014 Aggarwal R, Harris A, Formaker C, Small EJ, Molina A, Griffin TW, Ryan CJ
• Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
  European urology 2014 Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, …
• Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ
• Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ
• Prostate cancer, version 1.2014.
  Journal of the National Comprehensive Cancer Network : JNCCN 2013 Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, …
• Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
  Journal of the National Cancer Institute 2013 Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, de Bono J, Sartor O
• Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
  Cancer 2013 Halabi S, Rini B, Escudier B, Stadler WM, Small EJ
• Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, Solomon NC, Small EJ
• Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate.
  Science translational medicine 2013 Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, Small EJ, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, Chen AP…
• Reply to C.M. Booth et al.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Goodwin PJ, Ballman KV, Small EJ, Levine M, Cannistra SA
• The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
  Cancer 2013 Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ, Alliance for Clinical Trials in Oncology
• Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM, Grant RP, de Bono JS, Scher HI
• Penile cancer: Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2013 Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP…
• Intermittent versus continuous androgen deprivation in prostate cancer.
  The New England journal of medicine 2013 Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, …
• Bladder cancer.
  Journal of the National Comprehensive Cancer Network : JNCCN 2013 Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie …
• Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
  Cancer medicine 2013 Cha E, Small EJ
• Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.
  Journal of the National Cancer Institute 2013 Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF
• Evaluation of treatment benefit in Journal of Clinical Oncology.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Goodwin PJ, Ballman KV, Small EJ, Cannistra SA
• Abiraterone in metastatic prostate cancer without previous chemotherapy.
  The New England journal of medicine 2012 Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD,…
• Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P,…
• Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients.
  Journal of immunology (Baltimore, Md. : 1950) 2012 Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L
• Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).
  The Journal of urology 2012 Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM
• Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
  Journal of the National Cancer Institute 2012 Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF
• The future of cancer treatment: will it include immunotherapy?
  Cancer cell 2012 Bluestone JA, Small EJ
• Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ
• Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
  Cancer 2011 Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ, Cancer and Leukemia Group B
• A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer.
  Oncology reports 2011 Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ
• Prostate cancer: evolution or revolution?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Small EJ, de Bono JS
• Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809.
  Cancer 2011 Hurwitz MD, Halabi S, Archer L, McGinnis LS, Kuettel MR, DiBiase SJ, Small EJ
• The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer.
  Clinical advances in hematology & oncology : H&O 2011 Small EJ, Penson DF, Sartor O
• Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ
• A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
  Cancer 2011 Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE
• Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
  Cancer 2010 Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ
• Bevacizumab and everolimus in renal cancer: a rational way forward.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Stadler WM, Phillips G, George DJ, Halabi S, Small E
• Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
  Urologic oncology 2010 Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ
• A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
  Cancer 2010 Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ, Cancer and Leukemia Group B
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
  The New England journal of medicine 2010 Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators
• Sipuleucel-T.
  Nature reviews. Drug discovery 2010 Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW
• Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ
• Castrate-resistant prostate cancer: therapeutic strategies.
  Expert opinion on pharmacotherapy 2010 Harzstark AL, Small EJ
• Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.
  Investigational new drugs 2010 Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M
• Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ
• Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de …
• Developing immunotherapy as legitimate therapy for patients with prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Small EJ, Fong L
• Emerging biological observations in prostate cancer.
  Expert review of anticancer therapy 2010 Shah S, Small E
• Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
  Clinical genitourinary cancer 2009 Bajorin DF, Halabi S, Small E
• The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.
  Clinical genitourinary cancer 2009 Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ
• A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM
• Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
  Cancer 2009 Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW
• Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ
• Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, Dipaola RS, Crawford ED
• Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ
• Immunotherapeutics in development for prostate cancer.
  The oncologist 2009 Harzstark AL, Small EJ
• A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.
  Annals of oncology : official journal of the European Society for Medical Oncology 2009 Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ, Cancer and Leukemia Group B
• Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
  Cancer research 2009 Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ
• Bladder cancer.
  Journal of the National Comprehensive Cancer Network : JNCCN 2009 Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ…
• Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
  Clinical genitourinary cancer 2009 Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI
• Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
  Cancer 2008 Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, Small E, Cancer Leukemia Group B
• Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ
• Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Fong L, Small EJ
• Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
  The Journal of urology 2008 Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ
• A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
  Clinical genitourinary cancer 2008 Dawson NA, Halabi S, Ou SS, Biggs DD, Kessinger A, Vogelzang N, Clamon GH, Nanus DM, Kelly WK, Small EJ, Cancer And Leukemia Group B
• Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.
  Cancer 2008 Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J, Small EJ
• von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
  The Journal of urology 2008 Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R
• CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.
  Blood 2008 Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L
• Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ
• Prostate cancer update: 2007.
  Current opinion in oncology 2008 Lin AM, Small EJ
• Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
  International journal of radiation oncology, biology, physics 2008 Hurwitz MD, Halabi S, Ou SS, McGinnis LS, Keuttel MR, Dibiase SJ, Small EJ
• Sipuleucel-T for the treatment of prostate cancer.
  Drugs of today (Barcelona, Spain : 1998) 2008 Harzstark AL, Small EJ
• Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, …
• p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
  Urology 2008 D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW, Cancer and Leukemia Group B
• Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
  Annals of oncology : official journal of the European Society for Medical Oncology 2008 Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ, Millard F, Bajorin DF, Small EJ, Cancer and Leukemia Group B
• A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
  BJU international 2008 Ryan CJ, Harzstark AH, Rosenberg J, Lin A, Claros C, Goldfine ID, Kerner JF, Small EJ, Youngren JF
• Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study.
  International journal of radiation oncology, biology, physics 2007 D'Amico AV, Halabi S, Tempany C, Titelbaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, Small EJ, Cancer and Leukemia Group B
• Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
  The Journal of urology 2007 Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ
• A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102.
  BJU international 2007 Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ, Cancer and Leukaemia Group B
• A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
  BJU international 2007 Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF
• Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development.
  The Lancet. Oncology 2007 Hsieh AC, Small EJ, Ryan CJ
• Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.
  Cancer 2007 Halabi S, Ou SS, Vogelzang NJ, Small EJ
• Management of hormone refractory prostate cancer.
  Current opinion in supportive and palliative care 2007 Lin AM, Small EJ
• Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
  Cancer 2007 Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ
• Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).
  Expert opinion on biological therapy 2007 Harzstark AL, Small EJ
• Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW
• A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
  Clinical genitourinary cancer 2007 Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ
• Immunotherapy for prostate cancer.
  Current oncology reports 2007 Fong L, Small EJ
• Prostate cancer update: 2006.
  Current opinion in oncology 2007 Lin AM, Small EJ
• Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
  Investigational new drugs 2007 Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C, Small EJ
• Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ
• A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP
• Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer.
  BJU international 2007 Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, Small EJ
• Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
  Urologic oncology 2007 Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V, Small EJ, Goldfine ID
• The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.
  The Journal of urology 2007 Halabi S, Vogelzang NJ, Ou SS, Small EJ
• Intermittent chemotherapy for metastatic hormone refractory prostate cancer.
  Critical reviews in oncology/hematology 2006 Lin AM, Ryan CJ, Small EJ
• High risk biochemical relapse and the timing of androgen deprivation therapy.
  The Journal of urology 2006 Ryan CJ, Small EJ
• Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study.
  Cancer 2006 Kornblith AB, Dowell JM, Herndon JE, Engelman BJ, Bauer-Wu S, Small EJ, Morrison VA, Atkins J, Cohen HJ, Holland JC
• The case for secondary hormonal therapies in the chemotherapy age.
  The Journal of urology 2006 Small EJ, Ryan CJ
• Bladder cancer. Clinical guidelines in oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2006 Montie JE, Abrahams NA, Bahnson RR, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson…
• A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
  BJU international 2006 Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ
• A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
  Cancer 2006 Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ, Cancer and Leukemia Group B
• Androgen deprivation therapy in locally advanced and metastatic prostate cancer.
  Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2006 Ryan CJ, Small EJ
• Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.
  Urologic oncology 2006 Lin AM, Hershberg RM, Small EJ
• Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.
  Urologic oncology 2006 Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P
• Sipuleucel-T (APC8015) for prostate cancer.
  Expert review of anticancer therapy 2006 So-Rosillo R, Small EJ
• Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D, Southwest Oncology Group Trial 9346 (INT-0162)
• Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
  BJU international 2006 Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM
• Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2006 Rini BI, Halabi S, Barrier R, Margolin KA, Avigan D, Logan T, Stadler WM, McCarthy PL, Linker CA, Small EJ, Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, Southwestern Oncology Group
• Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies.
  The Journal of urology 2006 Halabi S, Vogelzang NJ, Ou SS, Kelly WK, Small EJ
• Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
  Cancer 2006 Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ
• Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM
• Activities and accomplishments of the cancer and leukemia group B genitourinary committee.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Small EJ, Halabi S, Kantoff P, D'Amico A, Stadler W, Kelley WK, Mohler J, Bajorin D, Vogelzang NJ
• Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.
  The Journal of urology 2006 Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ
• A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
  Molecular therapy : the journal of the American Society of Gene Therapy 2006 Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G
• Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
  Urologic oncology 2006 Ryan CJ, Lin AM, Small EJ
• Clinical trials in patients with biochemically relapsed prostate cancer.
  BJU international 2006 Lin AM, Rini BI, Small EJ
• Immunotherapy for prostate cancer.
  Current urology reports 2006 Fong L, Small EJ
• Prostate cancer update: 2005.
  Current opinion in oncology 2006 Ryan CJ, Small EJ
• Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
  Cancer 2006 Wilding G, Soulie P, Trump D, Das-Gupta A, Small E
• Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
  Journal of the National Cancer Institute 2006 Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED
• Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.
  Clinical genitourinary cancer 2006 Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW
• Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
  Cancer 2006 Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R, Simko J, Small EJ
• A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.
  Cancer 2006 Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ
• Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW, Cancer and Leukemia Group B
• Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Ryan CJ, Small EJ
• Prostate cancer immunology: biology, therapeutics, and challenges.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Webster WS, Small EJ, Rini BI, Kwon ED
• Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
  Cancer 2005 Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED
• Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer.
  Clinical prostate cancer 2005 Garcia JA, Weinberg V, Small EJ
• Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
  Urology 2005 Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW
• Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Ross RW, Manola J, Hennessy K, Galsky M, Scher H, Small E, Kelly WK, Kantoff PW
• Update on chemotherapy for advanced bladder cancer.
  The Journal of urology 2005 Rosenberg JE, Carroll PR, Small EJ
• Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.
  Clinical prostate cancer 2005 Beinart G, Rini BI, Weinberg V, Small EJ
• Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Stadler WM, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, Mahoney J, Ratain MJ
• A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
  Cancer 2005 Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D, Palmer PA, Perez-Ruixo JJ, Small EJ
• Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS
• Progress in detection and treatment of prostate cancer.
  Current opinion in oncology 2005 Ryan CJ, Small EJ
• Secondary hormonal manipulations in prostate cancer.
  Current oncology reports 2005 Ryan CJ, Small EJ
• Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Halabi S, Small EJ, Vogelzang NJ
• High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer.
  American journal of clinical oncology 2005 Chaudhary UB, Damon LE, Rugo HS, Linker CA, Navarro W, Small EJ
• Lifestyle correlates of health perception and treatment satisfaction in a clinical cohort of men with prostate cancer.
  Clinical prostate cancer 2005 Sheriff SK, Shohara RA, Dumican SB, Small EJ, Carroll PR, Chan JM
• Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK
• The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2005 George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW
• A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
  Cancer 2005 Rini BI, Weinberg V, Small EJ
• Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF).
  Cytokine 2005 Rini B, Wadhwa M, Bird C, Small E, Gaines-Das R, Thorpe R
• Bladder cancer. Clinical practice guidelines in oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2005 Montie JE, Bahnson RR, Cohen SM, Drucker B, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Seigne J, Shipley WU, Small EJ, Trump DL, Walther PJ,…
• Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
  Cancer 2004 Ahles TA, Herndon JE, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC, Cancer and Leukemia Group B
• Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Rini BI, Small EJ
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
  The New England journal of medicine 2004 Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED
• Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
  Cancer 2004 Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW
• 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
  Urologic oncology 2004 Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang N, Small E
• Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?
  Clinical prostate cancer 2004 Rosenberg JE, Small EJ
• Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ
• Impact of race on survival in men with metastatic hormone-refractory prostate cancer.
  Urology 2004 Halabi S, Small EJ, Vogelzang NJ, Barrier RC, George SL, Gilligan TD
• Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma.
  Cancer 2004 Rini BI, Weinberg V, Shaw V, Scott J, Bok R, Park JW, Small EJ
• Monoclonal antibody therapy for prostate cancer: finally a reality?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Small EJ
• Practice and progress in kidney cancer: methodology for novel drug development.
  The Journal of urology 2004 Rini BI, Weinberg V, Small EJ
• Advances in prostate cancer.
  Current opinion in oncology 2004 Ryan CJ, Small EJ
• The selection of hormonal therapy in prostate cancer: who, when, and for how long?
  Journal of the National Comprehensive Cancer Network : JNCCN 2004 Ryan CJ, Small EJ
• Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL, Cancer and Leukemia Group B
• Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ
• Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Higano CS, Vogelzang NJ, Sosman JA, Feng A, Caron D, Small EJ
• Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C,…
• Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
  Urology 2003 Eastham JA, Kelly WK, Grossfeld GD, Small EJ, Cancer and Leukemia Group B
• Role of secondary hormonal therapy in the management of recurrent prostate cancer.
  Urology 2003 Ryan CJ, Small EJ
• A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
  Cancer 2003 Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ, Cancer and Leukemia Group B 99813
• The evolving role of androgen deprivation therapy in the management of prostate cancer.
  Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2003 Cooperberg MR, Small EJ, D'Amico A, Carroll PR
• Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003 Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO
• Immunotherapy for prostate cancer.
  Seminars in oncology 2003 Fong L, Small EJ
• Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003 Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ, Cancer and Leukemia Group B Study 9663
• The potential for prostate cancer immunotherapy.
  Critical reviews in oncology/hematology 2003 Rini BI, Small EJ
• Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2003 LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, …
• Prostate cancer update.
  Current opinion in oncology 2003 Rosenberg J, Small EJ
• Overview of bladder cancer trials in the Cancer and Leukemia Group B.
  Cancer 2003 Small EJ, Halabi S, Dalbagni G, Pruthi R, Phillips G, Edelman M, Bajorin D, Cancer and Leukemia Group B
• Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003 Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ
• Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003 Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW
• Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003 Rini BI, Weinberg V, Bok R, Small EJ
• Complementary and alternative therapies in prostate cancer.
  Seminars in oncology 2002 Oh WK, Small EJ
• Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM
• Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ
• Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
  The Journal of urology 2002 Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ
• Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer.
  Clinical prostate cancer 2002 Harris KA, Harney E, Small EJ
• Prostate cancer update.
  Current opinion in oncology 2002 Rini BI, Small EJ
• PC-SPES and prostate cancer.
  The Urologic clinics of North America 2002 Oh WK, Small EJ
• Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy.
  Urology 2001 Grossfeld GD, Small EJ, Lubeck DP, Latini D, Broering JM, Carroll PR
• Secondary hormonal manipulation of prostate cancer.
  Current urology reports 2001 Harris KA, Small EJ
• Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
  Cancer research 2001 Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ
• Hormonal treatment for prostate cancer.
  Expert opinion on investigational drugs 2001 Harris KA, Small EJ
• Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001 Small EJ, McMillan A, Meyer M, Chen L, Slichenmyer WJ, Lenehan PF, Eisenberger M
• Docetaxel in prostate cancer.
  Anti-cancer drugs 2001 Small EJ
• Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000 Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH
• Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000 Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM
• Management of a positive surgical margin after radical prostatectomy: decision analysis.
  The Journal of urology 2000 Grossfeld GD, Tigrani VS, Nudell D, Roach M, Weinberg VK, Presti JC, Small EJ, Carroll PR
• Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000 Small EJ, Lew D, Redman BG, Petrylak DP, Hammond N, Gross HM, Eastham JA, Crawford ED
• A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma.
  Investigational new drugs 2000 Small EJ, Figlin R, Petrylak D, Vaughn DJ, Sartor O, Horak I, Pincus R, Kremer A, Bowden C
• An update on prostate cancer research.
  Current opinion in oncology 2000 Small EJ, Reese DM
• Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000 Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M
• Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma.
  Cancer 2000 Reese DM, Corry M, Small EJ
• New treatment strategies in advanced prostate cancer.
  Radiologic clinics of North America 2000 Small EJ, Reese DM
• Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis.
  Urology 2000 Tigrani VS, Reese DM, Small EJ, Presti JC, Carroll PR
• Outpatient combination chemoimmunotherapy for patients with metastatic melanoma. Results of a phase I/II trial.
  Cancer 1999 Kashani-Sabet M, Sagebiel RW, Collins HE, Glassberg AB, Allen RE, Leong SP, Small EJ
• Hormone-refractory prostate cancer: an evolving standard of care.
  Seminars in oncology 1999 Small EJ, Reese DM, Vogelzang NJ
• Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
  Clinical cancer research : an official journal of the American Association for Cancer Research 1999 Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD
• Advances in prostate cancer.
  Current opinion in oncology 1999 Small EJ
• Secondary hormonal manipulations in hormone refractory prostate cancer.
  The Urologic clinics of North America 1999 Reese DM, Small EJ
• The treatment of advanced prostate cancer with ketoconazole: safety issues.
  Drug safety 1999 Bok RA, Small EJ
• Diffuse retroperitoneal amyloidosis due to renal cell carcinoma.
  The British journal of radiology 1999 Coakley FV, Hricak H, Presti JC, Small EJ
• Long-term side effects of treatment for testis cancer.
  The Urologic clinics of North America 1998 Grossfeld GD, Small EJ
• Stage II nonseminomatous testis cancer: the roles of primary and adjuvant chemotherapy.
  The Urologic clinics of North America 1998 Frohlich MW, Small EJ
• Prostate cancer, Incidence, management and outcomes.
  Drugs & aging 1998 Small EJ
• The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon.
  The cancer journal from Scientific American 1998 Small EJ, Weiss GR, Malik UK, Walther PJ, Johnson D, Wilding G, Kuzel T, Bajamonde A, Paton V
• Update on the diagnosis and treatment of prostate cancer.
  Current opinion in oncology 1998 Small EJ
• Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.
  Urology 1998 Grossfeld GD, Small EJ, Carroll PR
• Pyrazoloacridine for the treatment of hormone-refractory prostate cancer.
  Cancer investigation 1998 Small EJ, Fippin LJ, Whisenant SP
• Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.
  Cancer 1997 Small EJ, Baron A, Bok R
• Prostate cancer.
  Current opinion in oncology 1997 Small EJ
• Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
  The Journal of urology 1997 Small EJ, Baron AD, Fippin L, Apodaca D
• Focal therapy for prostate cancer 1996: maximizing outcome.
  Urology 1997 Carroll PR, Presti JC, Small E, Roach M
• Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997 Small EJ, Vogelzang NJ
• Cancer and Leukemia Group B trials for advanced prostate cancer.
  Seminars in oncology 1996 Small EJ, Dawson NA, Kantoff PW, Vogelzang NJ
• Radiotherapy for high grade clinically localized adenocarcinoma of the prostate.
  The Journal of urology 1996 Roach M, Meehan S, Kroll S, Weil M, Ryu J, Small EJ, Margolis LW, Presti J, Carroll PC, Phillips TL
• A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium.
  Cancer 1996 Small EJ, Fippin LJ, Ernest ML, Carroll PR
• Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping.
  Cancer research 1996 Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH
• The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
  Cancer 1995 Small EJ, Srinivas S
• Malignant germ cell tumors in men infected with the human immunodeficiency virus: natural history and results of therapy.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995 Timmerman JM, Northfelt DW, Small EJ
• A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
  Cancer 1994 Small EJ, Frye JW, Wilkinson MJ, Carroll PR, Ernest ML, Stagg RJ
• Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome.
  Urology 1994 Small EJ, Carroll PR
• Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens.
  Journal of surgical oncology 1994 Wolf JS, Aronson FR, Small EJ, Carroll PR
• Prostate cancer: who to screen, and what the results mean.
  Geriatrics 1993 Small EJ
• Gallium-avid thymic hyperplasia in an adult after chemotherapy for Hodgkin disease.
  Cancer 1993 Small EJ, Venook AP, Damon LE
• A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
  Cancer 1993 Wilkinson MJ, Frye JW, Small EJ, Venook AP, Carroll PR, Ernest ML, Stagg RJ